In a report released yesterday, Arlinda Lee from Canaccord Genuity maintained a Buy rating on Harpoon Therapeutics (HARP), with a price target of $30.00. The company’s shares closed last Wednesday at $13.08.
According to TipRanks.com, Lee is a 4-star analyst with an average return of 10.9% and a 49.2% success rate. Lee covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Deciphera Pharmaceuticals.
Currently, the analyst consensus on Harpoon Therapeutics is a Moderate Buy with an average price target of $32.50, a 134.3% upside from current levels. In a report issued on December 8, Piper Sandler also maintained a Buy rating on the stock with a $35.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.02 and a one-year low of $10.27. Currently, Harpoon Therapeutics has an average volume of 143.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. It offers Tri-specific T cell Activating Construct (TriTACs) that focuses on the treatment of solid tumors and hematologic malignancies. The company founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.
